Are BPC-157 and Other Peptides Legal Now?
Are BPC-157 and other peptides legal now after the October 2026 HHS change?
Reviewed by Taylor Anderson, RN
Aesthetic Registered Nurse
Taylor Anderson is an aesthetic registered nurse and a reviewer for Hot or Nothing.
Updated October 30, 2026
Quick answer
For a slow-healing injury, BPC-157 is now easier to get through a licensed pharmacy that mixes it to a prescription written for you. On Oct 28, 2026, HHS said it won't take action against those pharmacies for BPC-157 and five other peptides. None is FDA approved, their legal status did not change, and research-chemical vials sit outside the policy.
Want your jeans to fit again? See which body options fit you and what they cost.
See My PlanIn this guide
Key takeaways
- On Oct 28, 2026, HHS said it won't take action against licensed compounding pharmacies or physicians that make BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 for a patient's own prescription.
- The policy is temporary and is not FDA approval, so the six peptides' legal status stays the same and HHS can change or withdraw the policy if safety or quality problems come up.
- People given BPC-157 knee injections mostly reported less pain and no side effects were reported, but FDA says it lacks the information to know whether any of the six causes harm in people.
- A covered product holds only one of the six peptides and uses an approved route, so a BPC-157 and TB-500 blend, BPC-157 nasal spray and vials sold online as research chemicals or supplements all fall outside the policy.
- Expect a wait, because pharmacy owners say they can't meet demand yet and ingredient suppliers must first meet the new quality requirements.
If you want BPC-157 for a slow-healing injury: on Oct 28, 2026, HHS said it won't take enforcement action against licensed 503A pharmacies or physicians that compound BPC-157 and five other peptides under set conditions. None of the six (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500) is FDA approved, and the policy does not change their legal status. Peptides sold online as research chemicals or supplements, and products that mix more than one of the six, sit outside the policy.
What changed on Oct 28, 2026, and what didn't?
HHS announced an interim policy on Oct 28, 2026. Under it, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500. The policy lasts while FDA keeps working on its rule for the 503A list, which sets the ingredients pharmacies may use when they mix a medicine for one patient's prescription, according to BakerHostetler's summary of the policy. The policy is not FDA approval. HHS calls it interim and says it may revise or withdraw it if safety or quality problems come up. Comments are open until two weeks after the notice publishes in the Federal Register.
In practice, compounding pharmacies can start offering the six now, even though the peptides are not on FDA's list of allowed ingredients, NBC News reported. Pharmacies must certify each peptide's identity and purity. They must also report side effects, which was not required before.
The peptides' legal status stays the same, NPR reported. At a July FDA advisory meeting, the panel voted for wider access, but FDA's own scientists at the same meeting recommended against lifting the restrictions. Critics pushed back. Public Citizen's Dr. Robert Steinbrook said HHS Secretary Robert F. Kennedy Jr. "has undermined the FDA and threatened public health," as NPR reported.
BPC-157 needed a policy at all because in September 2023, FDA placed it in Category 2, which effectively barred pharmacies from compounding it, as a 2025 review of BPC-157 for musculoskeletal healing explains. For the full history, see whether BPC-157 is legal.
What are the six peptides, and what is the evidence?
None of the six is FDA approved, and the uses people promote them for are unproven, NPR reported.
| Peptide | Promoted use | Human evidence | FDA safety note | Routes allowed under the policy |
|---|---|---|---|---|
| BPC-157 | Ulcerative colitis (NPR) | Three small published pilot studies. One looked back at knee injections in 16 people with no control group, and 14 reported pain relief. One gave bladder injections to 12 people with interstitial cystitis. One gave IV infusions to 2 healthy adults to test tolerance. No large trials (McGuire et al. 2025 review). FDA found no or only limited safety information for the proposed routes (FDA safety notes). | Possible immune reaction, meaning the body reacts to the peptide as something foreign. FDA says it lacks the information to know whether it causes harm in people (FDA safety notes). | Under the skin, into the muscle, by mouth or on the skin (BakerHostetler) |
| TB-500 | Wound healing (NPR) | FDA found no human exposure data (FDA safety notes). | Possible immune reaction. FDA says it lacks the information to know whether it causes harm in people (FDA safety notes). | Injection under the skin or into the muscle (BakerHostetler) |
| Epitalon | Insomnia (NPR) | FDA found no safety information for the proposed route (FDA safety notes). | Possible immune reaction. FDA says it lacks the information to know whether it causes harm in people (FDA safety notes). | Injection under the skin or into the muscle, given in courses with breaks (BakerHostetler) |
| KPV | Wound healing (NPR) | FDA found no human exposure data (FDA safety notes). | FDA says it lacks the information to know whether it causes harm in people (FDA safety notes). | On the skin or by mouth (BakerHostetler) |
| MOTS-c | Metabolic health (NPR) | FDA found no human exposure data (FDA safety notes). | FDA describes the risk of an immune reaction as significant. FDA says it lacks the information to know whether it causes harm in people (FDA safety notes). | Injection under the skin or into the muscle (BakerHostetler) |
| Semax | Migraine (NPR) | FDA found no or only limited safety information for the proposed route (FDA safety notes). | Possible immune reaction. FDA says it lacks the information to know whether it causes harm in people (FDA safety notes). | Nasal spray (BakerHostetler) |
FDA's risk page lists all six nominations as withdrawn but keeps its risk notes posted, so a withdrawn nomination is not a finding that a peptide is safe.
If you're weighing the two injury peptides against each other, see how BPC-157 and TB-500 compare for injuries.
Can you get BPC-157 from a pharmacy now?
Only from a licensed 503A compounding pharmacy or a licensed physician, with a prescription written for you, under the conditions HHS set. Here is what the policy covers and what it leaves out.
- One peptide per product. Each product can hold only one of the six, so a single vial with BPC-157 and TB-500 together falls outside the policy.
- Listed routes only. Routes must match the list in the table above, so BPC-157 nasal spray is not covered.
- Oral BPC-157 needs proof it's absorbed. A pill or liquid you swallow needs documented proof that the body absorbs it.
- Several sources sit outside the policy. Products sold as research chemicals or dietary supplements are not covered. Larger 503B outsourcing facilities are not covered either (BakerHostetler).
- Expect a wait. Pharmacy owner Joshua Fritzler told NPR, "We won't be able to meet demand." Alliance for Pharmacy Compounding CEO Scott Brunner called the policy a "more accountable alternative" to the gray market, but warned that dispensing may take time because ingredient suppliers must meet the new requirements and pharmacies must verify them.
- How to check a covered product. The raw peptide must come from an FDA-registered manufacturer that follows good manufacturing rules, with a valid certificate of analysis (the lab report on what is in the batch). The label must read "This is a compounded drug product. Not for resale." The only device packed with it can be an FDA-cleared syringe (BakerHostetler). Here's how to check a 503A pharmacy's license and inspection report, and how to read a peptide certificate of analysis.
Are these peptides safe now that pharmacies can make them?
The policy doesn't answer that. It decides which pharmacies HHS won't pursue, not whether a peptide is safe, and FDA's notes in the table above say it lacks the information to know whether any of the six causes harm in people.
For BPC-157, the three small human studies reported no side effects. The reviewers point out that every published BPC-157 study reported positive results, which suggests negative ones may never have been published. One theoretical worry is abnormal growth of new blood vessels, a process tied to tumor growth (McGuire et al. 2025 review).
Vials sold online as research chemicals or supplements sit outside the policy. That means the identity and purity certification and side-effect reporting that covered pharmacies now follow don't apply to them. Tell your clinical team about any peptide you use, including vials bought online.
As of Oct 30, 2026: HHS's notice is scheduled to publish in the Federal Register on Oct 30, and FDA's 503A rulemaking is still in progress.
If a slow-healing injury or slow recovery is why you're reading about BPC-157, take the quiz. Our clinical team reviews your goal and health history and suggests a plan that fits. You can also browse the body treatments Hot or Nothing offers.
Ready to make a move?
Answer three questions to see the treatment options that fit your goals.
See My PlanFAQ
What is BPC-157's FDA status in 2026?
BPC-157 is still not FDA approved, and its legal status did not change in 2026. FDA placed it in Category 2 in September 2023, which effectively stopped pharmacies from compounding it. On Oct 28, 2026, HHS said it won't take action against licensed 503A pharmacies or physicians that compound it under set conditions while FDA keeps working on its ingredient rule. FDA still says it lacks the information to know whether BPC-157 causes harm in people.
Is it still legal to buy research use only BPC-157 online?
The Oct 28, 2026 policy does not cover BPC-157 sold online as a research chemical or dietary supplement, so nothing changed for those vials. Only products compounded by a licensed pharmacy or physician for a prescription written for you fall under the policy. Research-chemical vials skip the identity and purity checks and side-effect reporting that covered pharmacies now follow. Tell your clinical team about any peptide you use, including vials bought online.
Is TB-500 legal now too?
TB-500 is covered by the same Oct 28, 2026 policy, so licensed 503A pharmacies can compound it for your own prescription without HHS taking action, but it is not FDA approved and its legal status did not change. The policy covers TB-500 only as an injection under the skin or into the muscle. It must be made on its own, so a vial that mixes TB-500 with BPC-157 is not covered. FDA says it found no human exposure data for TB-500.
When will compounding pharmacies start selling BPC-157?
Pharmacies can start offering BPC-157 now under the policy, but expect a wait before it is easy to get. Ingredient suppliers must first meet the new requirements and pharmacies must verify them, and one Florida pharmacy owner told NPR, "We won't be able to meet demand." Larger 503B outsourcing facilities are not covered, which limits how much can be made. You can take the quiz now so your clinical team can review whether a recovery plan fits you.
Keep reading
Sources (5)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing - PMC · pmc.ncbi.nlm.nih.gov · captured October 30, 2026
- HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances | BakerHostetler · bakerlaw.com · captured October 30, 2026
- RFK Jr. takes shortcut to make some unapproved peptides available for use · nbcnews.com · captured October 30, 2026
- Small compounding pharmacies won't be penalized for making peptides : NPR · npr.org · captured October 30, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA · fda.gov · captured October 30, 2026